ME03754B - Derivaтi karbazola - Google Patents

Derivaтi karbazola

Info

Publication number
ME03754B
ME03754B MEP-2019-363A MEP2019363A ME03754B ME 03754 B ME03754 B ME 03754B ME P2019363 A MEP2019363 A ME P2019363A ME 03754 B ME03754 B ME 03754B
Authority
ME
Montenegro
Prior art keywords
carboxamide
carbazole
fluoro
tetrahydro
hydroxypropan
Prior art date
Application number
MEP-2019-363A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Saleem Ahmad
Douglas G Batt
Qingjie Liu
John E Macor
Joseph A Tino
Scott Hunter Watterson
Satheesh Kesavan Nair
Tarun Kumar Maishal
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54427879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03754(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ME03754B publication Critical patent/ME03754B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MEP-2019-363A 2014-10-24 2015-10-23 Derivaтi karbazola ME03754B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068234P 2014-10-24 2014-10-24
EP15790408.7A EP3209651B9 (en) 2014-10-24 2015-10-23 Carbazole derivatives
PCT/US2015/057077 WO2016065236A1 (en) 2014-10-24 2015-10-23 Carbazole derivatives

Publications (1)

Publication Number Publication Date
ME03754B true ME03754B (me) 2021-04-20

Family

ID=54427879

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-363A ME03754B (me) 2014-10-24 2015-10-23 Derivaтi karbazola

Country Status (34)

Country Link
US (3) US10266491B2 (enExample)
EP (1) EP3209651B9 (enExample)
JP (1) JP6599983B2 (enExample)
KR (1) KR102514914B1 (enExample)
CN (1) CN107074804B (enExample)
AR (1) AR102427A1 (enExample)
AU (1) AU2015335703B2 (enExample)
BR (1) BR112017007545A2 (enExample)
CA (1) CA2965523A1 (enExample)
CL (1) CL2017001001A1 (enExample)
CO (1) CO2017004517A2 (enExample)
CY (1) CY1122549T1 (enExample)
DK (1) DK3209651T3 (enExample)
EA (1) EA032361B1 (enExample)
ES (1) ES2761903T3 (enExample)
HR (1) HRP20192197T2 (enExample)
HU (1) HUE048321T2 (enExample)
IL (1) IL251798B (enExample)
LT (1) LT3209651T (enExample)
MA (1) MA40302B1 (enExample)
ME (1) ME03754B (enExample)
MX (1) MX374724B (enExample)
MY (1) MY190568A (enExample)
PE (1) PE20171239A1 (enExample)
PH (1) PH12017500724B1 (enExample)
PL (1) PL3209651T3 (enExample)
PT (1) PT3209651T (enExample)
RS (1) RS59707B1 (enExample)
SG (2) SG11201703187PA (enExample)
SI (1) SI3209651T1 (enExample)
SM (1) SMT202000035T1 (enExample)
TN (1) TN2017000158A1 (enExample)
TW (1) TWI676618B (enExample)
WO (1) WO2016065236A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6588027B2 (ja) 2014-10-24 2019-10-09 武田薬品工業株式会社 複素環化合物
CN107108555B (zh) * 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
EP3481831B1 (en) * 2016-07-07 2023-09-06 Daewoong Pharmaceutical Co., Ltd. 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical composition comprising the same
GB201616627D0 (en) 2016-09-30 2016-11-16 Mission Therapeutics Limited Novel compounds
US10807951B2 (en) 2017-10-13 2020-10-20 The Regents Of The University Of California mTORC1 modulators
CN109053542A (zh) * 2018-07-25 2018-12-21 南通大学 一种6-溴-5-羟基异吲哚啉-1-酮的化学合成方法
CN114829350B (zh) * 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
CN110862396B (zh) * 2019-11-29 2021-06-04 浙江工业大学 一种吡咯并[3,4-c]咔唑-1,3(2H，6H)-二酮类化合物的合成方法
WO2021207549A1 (en) * 2020-04-10 2021-10-14 Gb005, Inc. Kinase inhibitors
CN115867346B (zh) * 2020-06-02 2025-03-14 Gb005股份有限公司 激酶抑制剂
CN115232061B (zh) * 2021-09-18 2024-01-30 山西紫罗蓝新材料科技有限公司 一种3-硝基-9-乙基咔唑粗产物的提取工艺
WO2024010784A1 (en) * 2022-07-06 2024-01-11 Vividion Therapeutics, Inc. Pharmaceutical compositions comprising wrn helicase inhibitors
AU2023353993A1 (en) * 2022-09-29 2025-04-03 Vividion Therapeutics, Inc. N-acryloylmorpholine derivatives as keap1 modulators and uses thereof
WO2026067706A1 (zh) * 2024-09-30 2026-04-02 杭州邦顺制药有限公司 Keap1调节剂

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
CA2140722A1 (en) 1994-01-24 1995-07-25 Joseph A. Jakubowski Beta-carboline thromboxane synthase inhibitors
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
WO2005047290A2 (en) 2003-11-11 2005-05-26 Cellular Genomics Inc. Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008519843A (ja) 2004-11-10 2008-06-12 シージーアイ ファーマスーティカル インコーポレーテッド 特定のイミダゾ［１，２−ａ］ビラジン−８−イラミンズ、その生成方法及びそれに関する使用方法
PL1831227T3 (pl) 2004-12-17 2013-10-31 Glenmark Pharmaceuticals Sa Nowe związki heterocykliczne użyteczne w leczeniu stanów zapalnych i dolegliwości alergicznych
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
EP1954290B1 (en) 2005-11-22 2012-07-25 Merck Sharp & Dohme Corp. Tricyclic compounds useful as inhibitors of kinases
JP2010502751A (ja) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法
CN101573348A (zh) 2006-09-11 2009-11-04 矩阵实验室有限公司 作为pde-4和pde-10的抑制剂的二苯并呋喃衍生物
US20090062251A1 (en) 2007-08-17 2009-03-05 Astrazeneca Ab Novel Compounds 002
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
EP2231143B1 (en) 2007-12-13 2013-07-03 Merck Sharp & Dohme Corp. 5H-pyrido[4,3-b]indoles as INHIBITORS OF JANUS KINASES
EP2599763A1 (en) 2008-02-14 2013-06-05 Siemens Molecular Imaging, Inc. Novel imaging agents for detecting neurological dysfunction
GB0809360D0 (en) 2008-05-22 2008-07-02 Isis Innovation Calcium modulation
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
EP2151441A1 (en) 2008-08-06 2010-02-10 Julius-Maximilians-Universität Würzburg Beta-carbolin-derivates as substrates for an enzyme
ES2443948T3 (es) * 2008-12-19 2014-02-21 Bristol-Myers Squibb Company Compuestos de carbazol carboxamida útiles como inhibidores de quinasas
CN101475571B (zh) 2009-01-21 2011-06-22 中国药科大学 β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途
ES2733093T3 (es) 2009-02-13 2019-11-27 Nextivity Inc Control remoto para amplificador
US8685969B2 (en) 2010-06-16 2014-04-01 Bristol-Myers Squibb Company Carboline carboxamide compounds useful as kinase inhibitors
EP2455378A1 (en) 2010-11-03 2012-05-23 Philip Morris Products S.A. Carbazole and carboline derivatives, and preparation and therapeutic applications thereof
CA2817896A1 (en) 2010-11-15 2012-05-24 Viiv Healthcare Uk Limited Inhibitors of hiv replication
ES2590491T3 (es) 2011-05-17 2016-11-22 F. Hoffmann-La Roche Ag Inhibidores de la tirosina quinasa de Bruton
TW201728592A (zh) 2012-01-10 2017-08-16 林伯士艾瑞斯公司 Ｉｒａｋ抑制劑及其用途
BR112015007513A2 (pt) 2012-10-26 2017-07-04 Hoffmann La Roche inibidores de tirosina quinase de bruton
AR096721A1 (es) * 2013-06-25 2016-01-27 Bristol Myers Squibb Co Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos
KR102345381B1 (ko) 2013-06-25 2021-12-29 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서 유용한 카르바졸 카르복스아미드 화합물
CN107108555B (zh) * 2014-10-24 2020-12-01 百时美施贵宝公司 三环阻转异构体化合物
MX393057B (es) 2014-10-24 2025-03-24 Bristol Myers Squibb Co Compuestos de indol carboxamida útiles como inhibidores de cinasas.

Also Published As

Publication number Publication date
TWI676618B (zh) 2019-11-11
PE20171239A1 (es) 2017-08-24
DK3209651T3 (da) 2020-02-03
US20200255377A1 (en) 2020-08-13
KR20170075756A (ko) 2017-07-03
IL251798A0 (en) 2017-06-29
MX374724B (es) 2025-03-06
CN107074804A (zh) 2017-08-18
RS59707B1 (sr) 2020-01-31
KR102514914B1 (ko) 2023-03-27
CA2965523A1 (en) 2016-04-28
EA032361B1 (ru) 2019-05-31
PT3209651T (pt) 2019-12-30
SG11201703187PA (en) 2017-05-30
AR102427A1 (es) 2017-03-01
MY190568A (en) 2022-04-27
TN2017000158A1 (en) 2018-10-19
CN107074804B (zh) 2020-02-18
SMT202000035T1 (it) 2020-03-13
US20190225583A1 (en) 2019-07-25
US20170362176A1 (en) 2017-12-21
HRP20192197T8 (hr) 2020-04-03
MA40302A1 (fr) 2018-05-31
AU2015335703B2 (en) 2020-05-21
PL3209651T3 (pl) 2020-03-31
CO2017004517A2 (es) 2017-08-31
EP3209651B9 (en) 2020-05-20
PH12017500724A1 (en) 2017-10-09
LT3209651T (lt) 2020-01-10
AU2015335703A1 (en) 2017-06-08
EP3209651A1 (en) 2017-08-30
SG10201903619YA (en) 2019-05-30
IL251798B (en) 2020-08-31
WO2016065236A1 (en) 2016-04-28
HRP20192197T1 (hr) 2020-03-06
US10266491B2 (en) 2019-04-23
JP6599983B2 (ja) 2019-10-30
MA40302B1 (fr) 2018-10-31
CY1122549T1 (el) 2021-01-27
HRP20192197T2 (hr) 2020-11-13
PH12017500724B1 (en) 2023-07-05
US10676434B2 (en) 2020-06-09
MX2017005255A (es) 2017-08-18
US11053197B2 (en) 2021-07-06
BR112017007545A2 (pt) 2017-12-19
JP2017535536A (ja) 2017-11-30
ES2761903T3 (es) 2020-05-21
CL2017001001A1 (es) 2017-11-24
TW201629014A (zh) 2016-08-16
SI3209651T1 (sl) 2019-12-31
EP3209651B1 (en) 2019-10-23
EA201790745A1 (ru) 2017-08-31
HUE048321T2 (hu) 2020-07-28

Similar Documents

Publication Publication Date Title
HRP20192197T2 (hr) Derivati karbazola
JP2017535536A5 (enExample)
JP7323723B2 (ja) Ｎａｖ１．８阻害剤としての２－オキソイミダゾリジン－４－カルボキサミド
US10072005B2 (en) 4-azaindole derivatives
KR101986484B1 (ko) 치환된 퀴놀린 및 이의 약제로서의 용도
JP5911638B2 (ja) ベンゾチアゾール−６−イル酢酸誘導体およびｈｉｖ感染を処置するためのそれらの使用
CN113164459B (zh) 单酰基甘油脂肪酶调节剂
IL281188B2 (en) Polycyclic compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
KR20190038666A (ko) 무스카린 m1 수용체 포지티브 알로스테릭 조절제
JP2014518267A5 (enExample)
EP3256463A1 (en) 1-(het)arylsulfonyl-(pyrrolidine or piperidine)-2-carboxamide derivatives and their use as trpa1 antagonists
HRP20192274T1 (hr) Novi derivati oktahidro-pirolo[3,4−c]-pirola i njihovi analozi kao inhibitori autotaksina
WO2018071606A1 (en) Compounds and methods for the targeted degradation of androgen receptor
JP2017510576A5 (enExample)
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
KR20150113019A (ko) Pim 키나제 저해제로서 유용한 티아졸카복스아마이드 및 피리딘카복스아마이드 화합물
HRP20191937T1 (hr) Derivati heksahidropirolo [3,4-c]pirola i srodni spojevi kao inhibitori autotaksina (atx) i kao inhibitori proizvodnje lizofosfatidne kiseline (lpa) za liječenje npr. bubrežnih bolesti
JP2014528479A5 (enExample)
JP2006506352A5 (enExample)
HK1226064A1 (zh) 作为trpm8拮抗剂的氮杂螺衍生物
KR20140104000A (ko) 신규한 바이사이클릭 다이하이드로이소퀴놀린-1-온 유도체
KR20140082743A (ko) 피라졸로퀴놀리논 유도체, 그의 제조 및 그의 치료적 용도
HRP20170484T1 (hr) Novi kondenzirani spojevi piridina kao inhibitori kazeinske kinaze
KR20150083833A (ko) Pi3 키나제 모듈레이터로서의 헤테로방향족 화합물 및 이의 이용 방법
AR084515A1 (es) Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras